Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kabi’s Sen Succeeds Sturm As Fresenius Chief

Head Of Fresenius Kabi Will Remain Leader Of Division Until A Successor Is Found

Executive Summary

Fresenius Kabi CEO Michael Sen is set to replace Fresenius group chief executive Stephan Sturm from the start of October. He will remain head of Kabi until a successor is appointed.

You may also be interested in...



Mabxience Sets Out Investment Plans Under Fresenius Ownership

Unveiling plans to install a new bioreactor at its Genhelix site in Spain, mAbxience is bolstering its biosimilars manufacturing capabilities and CDMO capacity under the majority ownership of Fresenius Kabi.

2022 Hires Reflect Global Challenges And Opportunities

Executive changes in 2022 reveal how the industry is adjusting to a volatile post-COVID environment.

Kabi ‘Overdelivering’ On Saving Plans But Feels The Sting Of Inflation

Newly instated Fresenius group CEO Michael Sen took charge of his first earnings call following his appointment on 1 October, pushing the message of Kabi managing its own destiny amid a series of macroeconomic challenges.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152119

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel